To view this content, you need to sign in.
You should only be asked to sign in once. Not the case? Click here
Register now to access this content and more for free.
Goldfinch Bio inks $100m Series B
Cambridge, Massachusetts-based Goldfinch Bio, a clinical stage biotechnology company focused on treating kidney diseases, has raised $100 million in Series B financing.
